Bull World Health Organ
September 2024
Most phase III trials in drug-resistant tuberculosis have either been underpowered to quantify differences in microbiological endpoints or have taken up to a decade to complete. Composite primary endpoints, dominated by differences in treatment discontinuation and regimen changes, may mask important differences in treatment failure and relapse. Although new regimens for drug-resistant tuberculosis appear very effective, resistance to new drugs is emerging rapidly.
View Article and Find Full Text PDFWe present an uncommon case of endocarditis caused by in an immunocompetent patient following a caesarean section. We discuss her turbulent admission course leading to her diagnosis following persistent bacteraemia, medical and surgical management, including a splenectomy and valve resection and repair, and subsequent prolonged course of combination antimicrobials for 24 months post valve surgery. The patient is alive 9 months after completing her treatment and 36 months after her valve surgery.
View Article and Find Full Text PDF